Data cast doubt on recommendation to delay weight-loss meds prior to surgery
Editor's Note A recent analysis of insurance claims data suggests weight-loss medications like Ozempic (semaglutide), Trulicity (dulaglutide), and other glucagon-like peptide-1 (GLP-1) receptor agonists do not increase risks associated with undergoing anesthesia. As reported April 22 in MedPage Today, these finding that contradicts a June 2023 recommendation from the American Society of…
Study: GLP weight loss, diabetes therapies boost GI endoscopy pneumonia risk
Editor's Note Gastrointestinal endoscopy could increase the risk of aspirational pneumonia in patients using GLP-1 receptor agonists (RAs) to manage weight or treat diabetes, according to an April 1 report from MedPage today. Citing research published in the journal Gastroenterology by a team led by Kevin Sheng-Kai Ma, DDS, of…
Study: Weight loss drugs could increase risk of surgical complications
Editor's Note Popular weight-loss drugs like Ozempic and Mounjaro could lead to complications in surgical procedures, according to study published March 6 in the journal JAMA Surgery. The study focused on drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) which are used to treat diabetes and obesity. The drugs, which…
Study: Bariatric surgery benefits glycemic control in Type 2 diabetes patients
Editor's Note Bariatric surgery is more effective than lifestyle and medical interventions in glycemic control for Type 2 diabetes patients, according to findings published February 27 in JAMA. The clinical trial involved four health systems and 262 participants, 96 of whom received medical- and lifestyle-focused treatment and 166 of whom…
ASA suggests patients stop popular weight loss medications before elective surgery
Editor's Note The American Society of Anesthesiologists (ASA) announced on June 29 that patients taking any of the currently popular medications for weight loss or for the treatment of type 2 diabetes should withhold the medication prior to elective surgery to "reduce the risk of complications associated with anesthesia in…
ECRI says it is time to review new evidence on weight-loss drugs
Editor's Note On January 10, ECRI released a new report calling on healthcare leaders to change their approach and embrace Food and Drug Administration (FDA)-approved weight loss drugs. ECRI says there is a large body of evidence showing that these drugs are beneficial as an adjunct to diet, exercise, and…
Free Daily News
- FDA medical device class 1 recalls trend upward
- Data cast doubt on recommendation to delay weight-loss meds prior to surgery
- AAMI guidance covers sterile processing of dilators, ultrasound probes
- Surgical site infections often caused by preexisting bacteria
- The Joint Commission launches new telehealth accreditation program
- FDA announces class 1 recall for disposable biopsy needle kit
- Report: Consistent, purposeful manager-team engagement reduces RN turnover
- Death, hospital readmission less likely for women treated by female doctors
- FDA announces class 1 recalls for infusion pumps, anesthesia workstation
- Study finds workforce readiness gap in new nurses